Keppra 750 mg film-coated tablets is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
Keppra is used:
- on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial onset seizures with or without secondary generalisation
- as an add-on to other antiepileptic medicines to treat: partial onset seizures with or without generalisation in patients from one month of age myoclonic seizures in patients from 12 years of age with juvenile myoclonic epilepsy primary generalised tonic-clonic seizures in patients from 12 years of age with idiopathic generalised epilepsy
Do not take Keppra
- If you are allergic (hypersensitive) to levetiracetam or any of the other ingredients of Keppra.
Take special care with Keppra
- If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted.
- If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.
- If you notice an increase in seizure severity (e.g. increased number), please contact your doctor.
- A small number of people being treated with anti-epileptics such as Keppra have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.
Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Taking Keppra with food and drink
You may take Keppra with or without food. As a safety precaution, do not take Keppra with alcohol.
Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
If you are pregnant or if you think you may be pregnant, please inform your doctor. Keppra should not be used during pregnancy unless clearly necessary. The potential risk to your unborn child is unknown. Keppra has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Breast-feeding is not recommended during treatment.
Driving and using machines
Keppra may impair your ability to drive or operate any tools or machinery, as Keppra may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.
Important information about some of the ingredients of Keppra
Keppra 750 mg contains Sunset Yellow FCF (E110). Sunset Yellow FCF (E110) coloring agent may cause allergic reactions.
Always take Keppra exactly as your doctor has told you. You should check with your doctor if you are not sure.
Keppra must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Take the number of tablets following your doctor’s instructions.
Dose in adults and adolescents (from 16 years of age):
General dose: between 1000 mg and 3,000 mg each day.
When you will first start taking Keppra, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose.
Example: if your daily dose is 3,000 mg, you must take 2 tablets in the morning and 2 tablets in the evening.
Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more:
General dose: between 1,000 mg and 3,000 mg each day.
Example: if your daily dose is 1,500 mg, you must take one tablet in the morning and one tablet in the evening.
Dose in infants (6 to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:
Your doctor will prescribe the most appropriate pharmaceutical form of Keppra according to the weight and dose. Keppra 100 mg/ml oral solution and Keppra 250 mg tablets are presentations more appropriate to infants and young children.
Dose in infants (1 month to less than 6 months):
Keppra 100 mg/ml oral solution is a presentation more appropriate to infants.
Method of administration:
Swallow Keppra tablets with a sufficient quantity of liquid ( e.g. a glass of water).
Duration of treatment:
- Keppra is used as a chronic treatment. You should continue Keppra treatment for as long as your doctor has told you.
- Do not stop your treatment without your doctor’s advice as this could increase your seizures. Should your doctor decide to stop your Keppra treatment, he/she will instruct you about the gradual withdrawal of Keppra.
If you take more Keppra than you should:
The possible side effects of an overdose of Keppra are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.
If you forget to take Keppra:
Contact your doctor if you have missed one or more doses.
Do not take a double dose to make up for a forgotten tablet.
If you stop taking Keppra:
If stopping treatment, as with other antiepileptic medicines, Keppra should be discontinued gradually to avoid an increase of seizures.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Keppra can cause side effects, although not everybody gets them. Tell your doctor if you have any of the following and they worry you.
Some of the side effects like sleepiness, tiredness and dizziness may be more common at the beginning of the treatment or at dose increase. These effects should however decrease over time.
The frequency of possible side effects listed below is defined using the following convention: Very common (affects more than 1 user in 10)
Common (affects 1 to 10 users in 100)
Uncommon (affects 1 to 10 users in 1,000)
Rare (affects 1 to 10 users in 10,000)
Very rare (affects less than 1 user in 10,000)
Not known (frequency cannot be estimated from the available data)
- somnolence (sleepiness);
- asthenia/fatigue (tiredness).
- infection, nasopharyngitis;
- decreased number of blood platelets;
- anorexia (loss of appetite), weight increase;
- agitation, depression, emotional instability/mood swings, hostility or aggression, insomnia, nervousness or irritability, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
- dizziness (sensation of unsteadiness), convulsion, headache, hyperkinesia (hyperactivity), ataxia (impaired coordinated movements), tremor (involuntary trembling), amnesia (loss of memory),
balance disorder (equilibrium disorder), disturbance in attention (loss of concentration), memory impairment (forgetfulness);
- diplopia (double vision), vision blurred;
- vertigo (sensation of rotation);
- cough (increase of pre-existing cough);
- abdominal pain, nausea, dyspepsia (indigestion), diarrhoea, vomiting;
- rash, eczema, pruritus;
- myalgia (muscle pain);
- accidental injury.
- decreased number of red blood cells, and/or white blood cells;
- weight loss;
- abnormal behaviour, anger, anxiety, confusion, hallucination, mental disorder, suicide, suicide attempt and suicidal ideation;
- paraesthesia (tingling);
- pancreatitis, hepatic failure, hepatitis, liver function test abnormal;
- hair loss, blistering of the skin, mouth, eyes and genital area, skin eruption.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use after the expiry date stated on the carton box and blister after EXP:.
The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions.
Keppra is a medicine that contains the active substance levetiracetam. It is available as oblong tablets (blue: 250 mg; yellow: 500 mg; orange: 750 mg; white: 1,000 mg), as an oral solution (100 mg/ml), and as a concentrate that is made up into a solution for infusion (drip into a vein, 100 mg/ml).
Keppra can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain.
Keppra can also be used as an add-on to other anti-epileptic medicines to treat:
- partial-onset seizures with or without generalisation in patients from one month of age;
- myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
- primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
The medicine can only be obtained with a prescription.
When Keppra is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day. The dose can be further increased at two-week intervals according to the patient’s response, to a maximum dose of 1,500 mg twice a day.
When Keppra is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day. The daily dose can be increased up to 1,500 mg twice a day. In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day. The oral solution is recommended when starting treatment in children weighing less than 20 kg. In babies aged between one and six months, the starting dose is 7 mg/kg twice a day, using the oral solution. This can be increased up to 21 mg/kg twice a day.
Lower doses are used in patients who have problems with their kidneys (such as older patients).
Keppra tablets are swallowed with liquid. The oral solution may be mixed in a glass of water before it is taken. Keppra can be given as an infusion using the same doses at the same frequency when using the tablets or the oral solution is not possible. The use of the infusion should be temporary.
The active substance in Keppra, levetiracetam, is an anti-epileptic medicine. Epilepsy is caused by excessive electrical activity in the brain. The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells. This helps Keppra to stabilise electrical activity in the brain and prevent seizures.
Keppra used on its own has been studied in 579 patients with partial-onset seizures aged 16 years and over, who received either Keppra or carbamazepine (another anti-epileptic medicine) for up to two years. The study measured how many patients remained free of seizures for six months once they had reached their effective dose.
Keppra has also been studied as an add-on treatment:
- in partial-onset seizures, it has been studied in three main studies in a total of 904 patients aged 16 years and over. In these studies, Keppra at doses of 1,000, 2,000 or 3,000 mg per day, was compared with placebo (a dummy treatment) over 12 to 14 weeks. All of the patients were taking at least one other anti-epileptic medicine. Keppra has also been compared with placebo in 314 patients aged between one month and 17 years;
- in myoclonic seizures, Keppra was studied in 122 patients aged 12 years and over, who received either Keppra or placebo in addition to their normal anti-epileptic medicine for up to 30 weeks;
- in primary generalised tonic-clonic seizures, Keppra was compared with placebo in 164 patients aged four years or over. The patient’s treatment was continued for 20 weeks once they were taking their full dose.
In all of these studies, the main measure of effectiveness was the change in the number of seizures before and during treatment.
Keppra was as effective as carbamazepine in keeping patients free of seizures when taken on its own for partial onset seizures. In both groups, 73% of the patients experienced no seizures for six months once on an adequate dose.
As an add-on treatment, Keppra was more effective than placebo:
- for partial onset seizures, placebo treatment reduced the weekly number of seizures by 6 to 7%, while the reduction with Keppra at a dose of 1,000 mg per day was between 18 and 33%, depending on the study. With Keppra at a dose of 2,000 mg, the reduction was 27%, and with 3,000 mg, it was around 39%. Keppra was also more effective than placebo in children;
- for myoclonic seizures, the number of seizure days per week was halved in 58% of the patients receiving Keppra and in 23% of the patients receiving placebo;
- for tonic-clonic seizures, the number of seizures fell by an average of 28% in the patients receiving placebo, compared with 57% in those receiving Keppra. However, there were too few patients aged below 12 years to support the use of Keppra for this type of seizure in this age group.
The most common side effects with Keppra (seen in more than 1 patient in 10) are somnolence (sleepiness), and asthenia (weakness) or fatigue (tiredness). For the full list of all side effects reported with Keppra, see the package leaflet.
Keppra should not be used in people who may be hypersensitive (allergic) to levetiracetam, to other pyrrolidone derivatives (medicines with a similar structure to levetiracetam), or to any of the other ingredients.
The CHMP decided that Keppra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union for Keppra on 29 September 2000. The marketing authorisation holder is UCB Pharma SA. After 10 years, the marketing authorisation was renewed for a further five years.
For more information about treatment with Keppra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 07-2010.